Sofinnova, OMX and Vækstfonden led a $19.5m Series A round in Freya Biosciences.

Synopsis

Sofinnova, a venture capital firm, OMX, a venture capital firm, and Vækstfonden, Denmark's investment fund, led a $19.5m Series A round in Freya Biosciences, a clinical-stage company taking an innovative approach to women's health.

Principals

target

Freya Biosciences Aps

bidder

Sofinnova Partners

Show Details & Financials

Did you work on this deal?

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Market Context

gorrissen federspiel

HQ - Copenhagen

legal advisors

target

305

Deals

£ 95.56 B

Total Value